A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis
- 41 Downloads
The efficacy of Shosaiko-to (SST) on 222 patients with chronic active hepatitis was studied in a double-blind multicenter clinical study. One hundred and sixteen patients received SST in a daily oral dose of 5.4 g for 12 weeks, followed by the same dose for a further 12 weeks. One hundred and six patients received a placebo containing 0.5 g of SST for 12 weeks, followed by a cross-over to SST for a further 12 weeks. Among the liver tests, serum AST and ALT values decreased significantly with the admisnistration of SST. The difference of the mean value between the SST group and the placebo group was significant after 12 weeks. In patients with chronic active type B hepatitis, a tendency towards a decrease of HBeAg and an increase of Anti-HBe antibodies was also observed. No remarkable side effects were noticed.
Key wordschronic active hepatitis Shosaiko-to
Unable to display preview. Download preview PDF.
- 1.Yamamoto M, Kumagai A, Yamamura Y: Structure and actions of saikosaponins isolated from Bupleurum falcatum L.I. Anti-inflammatory action of saikosaponins. Arzneim Forsch 1975;25:102M023Google Scholar
- 5.Mizuta M, Murata K, Morimoto T, et al: Therapeutical evaluation of Shosaiko-to on chronic hepatitis-Study on double-Wine test -. Kan Tan Sui 1986;12:155–168 (in Jpn)Google Scholar
- 9.Ikemoto Y, Mizoguchi Y, Arai T, et al: Effects of Shosaiko-To (Xiao-Chai-Hu-Tang) and Daisaiko-To (Da-Chai-Hu-Tang) on antibody response in vitro. J Med Soc Wakan-yaku 1984;1:235–242 (in Jpn)Google Scholar